Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2167-2175

  Pedersen, Astrid M ^a   Thrane, Susan ^a   Lykesfeldt, Anne E ^a   Yde, Christina W ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Breast cancer; Cell signaling; Estrogen receptor; Receptor tyrosine kinase inhibitors; Tamoxifen resistance

Indexed keywords

CASPASE; CATHEPSIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PROTEIN KINASE B; SORAFENIB; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; CARBANILAMIDE DERIVATIVE; ESTROGEN RECEPTOR ALPHA, HUMAN; FOXA1 PROTEIN, HUMAN; NCOA3 PROTEIN, HUMAN; NICOTINAMIDE; PYRIMIDINE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TAMOXIFEN RESISTANT BREAST CANCER; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MCF-7 CELLS; NIACINAMIDE; NUCLEAR RECEPTOR COACTIVATOR 3; PHENYLUREA COMPOUNDS; PYRIMIDINES; TAMOXIFEN;

EID: 84907192025     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2619     Document Type: Article

References (42)

1. Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378: 771-784, 2011.
2. Dutertre M and Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295: 431-437, 2000.
3. Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS and Yde CW: Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat 139: 71-80, 2013.
4. Lavinsky RM, Jepsen K, Heinzel T, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925, 1998.
5. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D and Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43: 27-33, 2011.
6. Xu J and Li Q: Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17: 1681-1692, 2003.
7. Font de Mora J and Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20: 5041-5047, 2000.
8. Bunone G, Briand PA, Miksicek RJ and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174-2183, 1996.
9. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.
10. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824, 2001.
11. Zwick E, Bange J and Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8: 161-173, 2001.
12. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
13. Plaza-Menacho I, Morandi A, Robertson D, et al: Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29: 4648-4657, 2010.
14. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
15. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
16. Luu T, Frankel P, Chung C, et al: Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer. Clin Breast Cancer 14: 94-100, 2014.
17. Baselga J, Costa F, Gomez H, et al: A phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (the RESILIENCE study): Study protocol for a randomized controlled trial. Trials 14: 228, 2013.
18. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
19. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A and Griffin JD: AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 94: 1765-1769, 2006.
20. O'Hare T, Walters DK, Deininger MW and Druker BJ: AMN107: Tightening the grip of imatinib. Cancer Cell 7: 117-119, 2005.
21. Piccaluga PP, Paolini S, Bertuzzi C, De Leo A and Rosti G: First-line treatment of chronic myeloid leukemia with nilotinib: Critical evaluation. J Blood Med 3: 151-156, 2012.
22. Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M and Martin LA: Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res 14: R78, 2012.
23. Briand P and Lykkesfeldt AE: Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res 44: 1114-1119, 1984.
24. Lykkesfeldt AE, Madsen MW and Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54: 1587-1595, 1994.
25. Lundholt BK, Briand P and Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 67: 199-214, 2001.
26. Larsen MS, Yde CW, Christensen IJ and Lykkesfeldt AE: Carboplatin treatment of antiestrogen-resistant breast cancer cells. Int J Oncol 41: 1863-1870, 2012.
27. Arnold SF, Obourn JD, Jaffe H and Notides AC: Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: Consequence on DNA binding. J Steroid Biochem Mol Biol 55: 163-172, 1995.
28. De Leeuw R, Neefjes J and Michalides R: A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011: 232435, 2011.
29. Chen D, Riedl T, Washbrook E, et al: Activation of estrogen receptor alpha by S118 phosphorylation involves a liganddependent interaction with TFIIH and participation of CDK7. Mol Cell 6: 127-137, 2000.
30. Wijayaratne AL and McDonnell DP: The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276: 35684-35692, 2001.
31. Osborne CK, Wakeling A and Nicholson RI: Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90 (Suppl 1): S2-S6, 2004.
32. Kroemer G and Jaattela M: Lysosomes and autophagy in cell death control. Nat Rev Cancer 5: 886-897, 2005.
33. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935, 2004.
34. Hodges LC, Cook JD, Lobenhofer EK, et al: Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 1: 300-311, 2003.
35. Vendrell JA, Bieche I, Desmetz C, et al: Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer 12: 75-92, 2005.
36. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361, 2003.
37. Su Q, Hu S, Gao H, et al: Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology 75: 159-168, 2008.
38. Smith CL, Nawaz Z and O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11: 657-666, 1997.
39. Reiter R, Oh AS, Wellstein A and Riegel AT: Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene 23: 403-409, 2004.
40. Rahmani M, Davis EM, Crabtree TR, et al: The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27: 5499-5513, 2007.
41. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006.
42. Shaker ME, Ghani A, Shiha GE, Ibrahim TM and Mehal WZ: Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochim Biophys Acta 1833: 1992-2003, 2013.